Alexion Pharmaceuticals, Inc. Fundamental Analysis
Alexion Pharmaceuticals, Inc. (ALXN) shows weak financial fundamentals with a PE ratio of 66.27, profit margin of 9.94%, and ROE of 5.26%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 69.4/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ALXN's fundamental strength across five key dimensions:
Efficiency Score
WeakALXN struggles to generate sufficient returns from assets.
Valuation Score
ModerateALXN shows balanced valuation metrics.
Growth Score
ModerateALXN shows steady but slowing expansion.
Financial Health Score
ExcellentALXN maintains a strong and stable balance sheet.
Profitability Score
WeakALXN struggles to sustain strong margins.
Key Financial Metrics
Is ALXN Expensive or Cheap?
P/E Ratio
ALXN trades at 66.27 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ALXN's PEG of -0.94 indicates potential undervaluation.
Price to Book
The market values Alexion Pharmaceuticals, Inc. at 3.43 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 0.40 times EBITDA. This is generally considered low.
How Well Does ALXN Make Money?
Net Profit Margin
For every $100 in sales, Alexion Pharmaceuticals, Inc. keeps $9.94 as profit after all expenses.
Operating Margin
Core operations generate 47.12 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.26 in profit for every $100 of shareholder equity.
ROA
Alexion Pharmaceuticals, Inc. generates $3.33 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $13.22 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
66.27
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.94
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.43
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.22
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.59
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.17
vs 25 benchmark
How ALXN Stacks Against Its Sector Peers
| Metric | ALXN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 66.27 | 29.97 | Worse (Expensive) |
| ROE | 5.26% | 389.00% | Weak |
| Net Margin | 9.94% | -13432.00% (disorted) | Weak |
| Debt/Equity | 0.22 | 0.78 | Strong (Low Leverage) |
| Current Ratio | 3.59 | 5.06 | Strong Liquidity |
| ROA | 3.33% | -295.00% (disorted) | Weak |
ALXN outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Alexion Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation